Juliet Wallace’s Post

Will your value proposition resonate with NHS decision-makers? Will your UK market access strategy work when applied to the real-world NHS? At Mtech Access, we have a network of Associates in key roles across the NHS, ready to share their insights and offer an insider perspective on your strategy. One client shared their experience of engaging with our network: “I was impressed by the calibre of the Associates in your network. It meant that we had the perfect experts to provide input on our UK market access strategy. The advisory board was well structured and engaging – 5/5 for facilitation! We have already made a start on the recommendations, and these have really helped us prioritise the different activities and shaped our thinking.” – Pricing, Reimbursement & Access Manager, Top 20 Pharma Company To learn more about how our team can help you shape and test your UK market access strategy, email info@mtechaccess.co.uk #NHSinsights #valueproposition #marketaccess #Pharma #Medtech #Pharmaceutical #medicaldevices

Will your value proposition resonate with NHS decision-makers? Will your UK market access strategy work when applied to the real-world NHS? At Mtech Access, we have a network of Associates in key roles across the NHS, ready to share their insights and offer an insider perspective on your strategy. One client shared their experience of engaging with our network: “I was impressed by the calibre of the Associates in your network. It meant that we had the perfect experts to provide input on our UK market access strategy. The advisory board was well structured and engaging – 5/5 for facilitation! We have already made a start on the recommendations, and these have really helped us prioritise the different activities and shaped our thinking.” – Pricing, Reimbursement & Access Manager, Top 20 Pharma Company To learn more about how we can help you shape and test your UK market access strategy, drop me a message or email info@mtechaccess.co.uk #NHSinsights #valueproposition #marketaccess #Pharma #Medtech #Pharmaceutical #medicaldevices

Will your value proposition resonate with NHS decision-makers? Will your UK market access strategy work when applied to the real-world NHS? We have a network of Associates in key roles across the NHS, ready to share their insights and offer an insider perspective on your strategy. One client shared their experience of engaging with our network: “I was impressed by the calibre of the Associates in your network. It meant that we had the perfect experts to provide input on our UK market access strategy. The advisory board was well structured and engaging – 5/5 for facilitation! We have already made a start on the recommendations, and these have really helped us prioritise the different activities and shaped our thinking.” – Pricing, Reimbursement & Access Manager, Top 20 Pharma Company To learn more about how our team can help you shape and test your UK market access strategy, email info@mtechaccess.co.uk #NHSinsights #valueproposition #marketaccess #Pharma #Medtech #Pharmaceutical #medicaldevices

𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐬𝐚𝐯𝐞𝐝 𝐲𝐨𝐮𝐫 𝐬𝐞𝐚𝐭? 📅 Join Paul Craddy and Graham Foxon on May 8th for the latest instalment of our #EUHTA webinar series! 🌍 Amidst the ongoing discussions and uncertainties surrounding EU HTA, including the joint clinical assessment and scoping process, our experts are poised to cut through the noise. They'll deliver an insightful session, guiding you from strategic planning to actionable steps, ensuring readiness for Jan 2025 👍 ✅ 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰: https://lnkd.in/eJnrTeRH Have any questions? Pop them in the comments below 🗨 #marketaccess #healthcare #pharmaceuticals #jca #jointclinicalassessment #healthtechnologyassessment #hta

📣 Countdown Begins: Just One Month Until Our 10th Annual Drugs & Devices Australia Webinar 2024! Join our Director George Papadopoulos and MedTechnique Consulting's Director, Sarah Griffin for their much-anticipated webinar on the latest developments in reimbursement strategies for the Australian market.   📌 When: 28 November, 8:30am AEST and 27 November 2024, 1:30pm PST. George and Sarah will share valuable insights on navigating the complex landscape of drug and device reimbursement applications. Together, they will review the key trends from the past year and address your questions live during the webinar.    To join please register here ➡ https://lnkd.in/ggzbYc6a Upon registration, you’ll receive a confirmation email with details on how to join the webinar.   We look forward to sharing our expertise, reflecting on the past year, and engaging with you during our 10th Annual Drugs & Devices Australia Reimbursement Update.     #reimbursement #marketaccess #medtech #pharmaceuticals #medicaldevices #healthcare #healtheconomics #webinar #lucidhealthconsulting

Is There a Trust Gap Between Pharma and HCPs? A strong relationship between pharmaceutical companies and healthcare professionals (HCPs) is crucial for advancing patient care. But is there a trust gap hindering collaboration? Our new infographic explores the current state of trust in the healthcare industry, highlighting: • How pharma and HCPs rank in terms of trust • The value of effective pharma-HCP interactions • Strategies to foster stronger collaboration See the infographic here: https://lnkd.in/ehtZj2fw #pharma #healthcare #HCPS #collaboration #infographic #emjreviews

🌍 𝐀𝐧𝐝 𝐭𝐡𝐚𝐭'𝐬 𝐚 𝐰𝐫𝐚𝐩 𝐟𝐨𝐫 𝐃𝐚𝐲 𝟑! 👏 This afternoon, we attended the final plenary session at #ISPOREurope 2024, "Reality Check: Are We Bridging the Evidence Gaps for Patients?" The discussion highlighted the need for stronger collaboration among stakeholders - regulators, HTA agencies, payers, and the pharmaceutical industry - to generate meaningful and reliable evidence that supports #patientaccess. Key themes included leveraging real-world data and clinical trials to meet diverse evidence needs, reducing uncertainties at every stage of decision-making, and ensuring innovative treatments reach patients as early as possible⚕ Want to know our 𝐤𝐞𝐲 𝐭𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐩𝐥𝐞𝐧𝐚𝐫𝐲? Check out our summary ➡ 𝐏𝐋𝐔𝐒... You can find all of our research and summaries on our 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐛𝐨𝐨𝐭𝐡, and for our newsletter subscribers, you'll receive a full report next week! If you're not a subscriber....sign up!! 👉 https://lnkd.in/exy8iWT6 📰 #marketaccess #heor #globalconference #hta #pharma #healthcare #pharmaceuticals 

Colonis Commercial Director Michael Dobson and Product Manager Fiona Wiles are attending 30th Medicines for Europe conference later this week in Dublin, where they will be exploring further opportunities for innovation in value-added medicines (VAMs).   Medicines for Europe have a mission to establish, in collaboration with patients, healthcare professionals and payers, a sustainable market model that incentivises R&D and access to VAMs. Here at Colonis Pharma we understand the importance of VAMs which contribute to addressing unmet patient needs, moving from a one-size-fits-all to a more patient specific approach. This is why we are continually investing in the repurposing and reformulation of existing drugs.     Find out more about VAMs at: https://lnkd.in/ef2Mhdch   #Pharmaceuticals #ValueAddedMedicines #MedicinesForEurope

This case study describes how we tackled a significant challenge for a European pharmaceutical company focused on a rare pediatric disorder that was in phase III clinical trials. Our goal was to understand the UK’s current practices, standards of care, and market access requirements. What We Did: • Conducted a thorough analysis of disease incidence and unmet needs • Assessed current treatment guidelines and identified gaps • Mapped key stakeholders and treatment networks • Gathered insights from leading clinical experts and patient groups to refine product profiling • Provided expert connections to align regulatory processes with market strategies • Developed recommendations for pricing submissions and market access strategies Results: We clarified the next steps for market access, regulatory, and communications, ensuring the company was ready for market entry pending pivotal phase III results. Curious to learn more? Click the link to read the full case study https://lnkd.in/eVrMGB3h #LifeSciences #Pharma #Marketentry #MarketAccess